INTEGRATING AYURVEDIC PHARMACOTHERAPY WITH CRITICAL CARE: A PHARMACOLOGICAL EVALUATION OF POTENTIAL THERAPEUTIC AND SAFETY OUTCOMES

Authors

  • Dr Ayan Purkayastha Author
  • Dr. Seema Sameer Choughule Author
  • Archana Rathore Author
  • (Dr) Kshirabdhi Tanaya Rautaray Author
  • Dr. Himanshu Kumar Author
  • Artha Rajagopal k Author

DOI:

https://doi.org/10.4238/a50ky609

Keywords:

Ayurvedic pharmacotherapy; Critical care; Herb–drug interactions; Pharmacokinetics; Integrative medicine

Abstract

Critical illness is characterized by profound inflammatory, oxidative, immune, metabolic, and microcirculatory disturbances that contribute to progressive organ dysfunction and complicate pharmacological management. Ayurvedic pharmacotherapy has attracted interest as a potential adjunctive approach because medicinal plants and complex formulations contain bioactive constituents capable of modulating multiple pathophysiological pathways. This review critically evaluates the pharmacological basis, potential therapeutic applications, safety considerations, and translational prospects of integrating Ayurvedic interventions into critical-care practice. Emphasis is placed on anti-inflammatory, antioxidant, immunomodulatory, mitochondrial, and endothelial mechanisms relevant to sepsis, acute respiratory distress syndrome, acute kidney injury, hepatic dysfunction, cardiovascular instability, and neurocritical illness. The review further examines altered pharmacokinetics and pharmacodynamics during critical illness, including herb–drug interactions involving cytochrome P450 enzymes, drug transporters, and commonly administered intensive-care medications. Major safety concerns include organ-specific toxicity, herbo-mineral exposure, contamination, adulteration, formulation variability, and inadequate pharmacovigilance. Current evidence remains limited by heterogeneous interventions, insufficient pharmacokinetic characterization, inconsistent standardization, and scarcity of rigorous intensive care trials. Future translation requires standardized formulations, mechanistic validation, dose optimization, biomarker-guided patient selection, multicenter randomized trials, and continuous safety surveillance. Ayurvedic pharmacotherapy may ultimately have adjunctive potential, but integration should remain evidence driven, pharmacologically justified, and subordinate to established critical-care standards and therapies.

Downloads

Published

2026-10-05

Issue

Section

Articles